This page shows Cartesian (RNAC) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Cartesian now operates as a cash-funded development-stage biotech, where R&D outlays overwhelm a shrinking revenue base.
Between FY2024 and FY2025, cash burn re-accelerated as operating cash outflow widened from$23.7M to$73.9M . With revenue down to$2.8M while R&D spending still ran at$58.0M , the business is being governed by development intensity and financing capacity rather than current sales.
Liquidity and solvency are telling different stories: cash and equivalents of
Today’s cash position was built externally, with FY2024 bringing in
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Cartesian's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Cartesian scores -4.67, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($238.9M) relative to total liabilities ($422.7M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Cartesian passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
For every $1 of reported earnings, Cartesian generates $0.57 in operating cash flow (-$73.9M OCF vs -$130.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Cartesian generated $2.8M in revenue in fiscal year 2025. This represents a decrease of 92.8% from the prior year.
Cartesian's EBITDA was -$140.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 248.3% from the prior year.
Cartesian reported -$130.3M in net income in fiscal year 2025. This represents a decrease of 68.3% from the prior year.
Cartesian earned $-5.02 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 11.8% from the prior year.
Cash & Balance Sheet
Cartesian generated -$79.4M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 142.3% from the prior year.
Cartesian held $125.1M in cash against $0 in long-term debt as of fiscal year 2025.
Cartesian had 26M shares outstanding in fiscal year 2025. This represents an increase of 0.9% from the prior year.
Margins & Returns
Cartesian's operating margin was -5127.1% in fiscal year 2025, reflecting core business profitability. This is down 5014.3 percentage points from the prior year.
Cartesian's net profit margin was -4658.6% in fiscal year 2025, showing the share of revenue converted to profit. This is down 4459.7 percentage points from the prior year.
Capital Allocation
Cartesian invested $58.0M in research and development in fiscal year 2025. This represents an increase of 28.7% from the prior year.
Cartesian invested $5.5M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 40.0% from the prior year.
RNAC Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $78K-91.8% | $947K+109.5% | $452K+51.7% | $298K-72.9% | $1.1M | N/A | $387K-98.8% | $33.4M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $19.5M+32.5% | $14.7M+6.4% | $13.8M-7.2% | $14.9M+1.3% | $14.7M | N/A | $11.4M-10.0% | $12.7M |
| SG&A Expenses | $7.1M-13.2% | $8.2M+6.2% | $7.7M+6.6% | $7.2M-12.9% | $8.3M | N/A | $6.6M-6.6% | $7.0M |
| Operating Income | -$26.5M+66.3% | -$78.6M-273.3% | -$21.1M+3.4% | -$21.8M+0.4% | -$21.9M | N/A | -$17.6M-227.8% | $13.8M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | $0 | $0 |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$39.2M+57.7% | -$92.6M-157.9% | -$35.9M-326.0% | $15.9M+189.7% | -$17.7M | N/A | -$24.2M-274.8% | $13.8M |
| EPS (Diluted) | $-1.46 | N/A | $-1.38-376.0% | $0.50+173.5% | $-0.68 | N/A | $-1.13-309.3% | $0.54 |
RNAC Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $288.4M-2.7% | $296.4M-20.5% | $372.7M-4.2% | $388.9M-4.9% | $409.1M-6.0% | $435.0M-4.5% | $455.3M+30.9% | $347.7M |
| Current Assets | $122.0M-5.6% | $129.3M-12.2% | $147.3M-9.9% | $163.4M-11.7% | $185.1M-14.5% | $216.6M-5.5% | $229.1M+83.6% | $124.8M |
| Cash & Equivalents | $118.6M-5.2% | $125.1M-12.7% | $143.4M-10.6% | $160.3M-11.1% | $180.4M-15.1% | $212.6M-3.0% | $219.2M+151.3% | $87.2M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $261K-76.6% | $1.1M+54.4% | $722K+104.0% | $354K-79.9% | $1.8M+102.4% | $872K-81.9% | $4.8M-84.9% | $32.0M |
| Goodwill | $48.2M0.0% | $48.2M0.0% | $48.2M0.0% | $48.2M0.0% | $48.2M0.0% | $48.2M0.0% | $48.2M0.0% | $48.2M |
| Total Liabilities | $436.5M+3.3% | $422.7M+3.5% | $408.5M+4.4% | $391.4M-9.2% | $430.9M-2.5% | $441.8M-2.8% | $454.6M+1.2% | $449.2M |
| Current Liabilities | $15.9M+6.7% | $14.9M+8.2% | $13.8M+12.6% | $12.3M-18.3% | $15.0M-34.7% | $23.0M+7.3% | $21.4M-18.0% | $26.1M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$148.1M-17.3% | -$126.2M-252.2% | -$35.8M-1318.4% | -$2.5M+88.4% | -$21.8M-220.3% | -$6.8M-1004.5% | $752K+100.7% | -$101.5M |
| Retained Earnings | -$861.6M-4.8% | -$822.4M-12.7% | -$729.8M-5.2% | -$693.9M+2.2% | -$709.8M-2.6% | -$692.1M-1.5% | -$681.8M-3.7% | -$657.6M |
RNAC Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$22.1M-25.0% | -$17.7M-13.5% | -$15.6M+11.0% | -$17.5M+24.2% | -$23.1M | N/A | $13.7M+194.8% | -$14.4M |
| Capital Expenditures | $27K-94.5% | $492K-61.9% | $1.3M-50.2% | $2.6M+141.4% | $1.1M | N/A | $6.2M+290.6% | $1.6M |
| Free Cash Flow | -$22.2M-21.7% | -$18.2M-7.8% | -$16.9M+16.0% | -$20.1M+16.8% | -$24.2M | N/A | $7.5M+146.7% | -$16.0M |
| Investing Cash Flow | -$27K+94.5% | -$492K+61.9% | -$1.3M+50.2% | -$2.6M-141.4% | -$1.1M | N/A | -$6.2M-290.6% | -$1.6M |
| Financing Cash Flow | $15.7M+30236.5% | -$52K-36.8% | -$38K-163.3% | $60K+100.7% | -$8.0M | N/A | $124.5M+103645.0% | $120K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
RNAC Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -33973.1%-25669.1pp | -8304.0%-3643.4pp | -4660.6%+2658.5pp | -7319.1%-5329.2pp | -1989.9% | N/A | -4541.3%-4582.5pp | 41.1% |
| Net Margin | -50233.3%-40457.6pp | -9775.7%-1832.8pp | -7942.9%-13273.8pp | 5330.9%+6940.9pp | -1610.0% | N/A | -6248.8%-6290.2pp | 41.4% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | -3215.8% | N/A |
| Return on Assets | -13.6%+17.6pp | -31.2%-21.6pp | -9.6%-13.7pp | 4.1%+8.4pp | -4.3% | N/A | -5.3%-9.3pp | 4.0% |
| Current Ratio | 7.65-1.0 | 8.65-2.0 | 10.67-2.7 | 13.33+1.0 | 12.34+2.9 | 9.43-1.3 | 10.70+5.9 | 4.78 |
| Debt-to-Equity | -2.95+0.4 | -3.35+8.0 | -11.40+143.5 | -154.90-135.1 | -19.78+45.2 | -64.96-669.4 | 604.47+608.9 | -4.43 |
| FCF Margin | -28412.8%-26490.5pp | -1922.3%+1814.9pp | -3737.2%+3013.2pp | -6750.3%-4551.9pp | -2198.5% | N/A | 1935.9%+1983.9pp | -47.9% |
Note: Shareholder equity is negative (-$126.2M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Frequently Asked Questions
What is Cartesian's annual revenue?
Cartesian (RNAC) reported $2.8M in total revenue for fiscal year 2025. This represents a -92.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Cartesian's revenue growing?
Cartesian (RNAC) revenue declined by 92.8% year-over-year, from $38.9M to $2.8M in fiscal year 2025.
Is Cartesian profitable?
No, Cartesian (RNAC) reported a net income of -$130.3M in fiscal year 2025, with a net profit margin of -4658.6%.
What is Cartesian's EBITDA?
Cartesian (RNAC) had EBITDA of -$140.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Cartesian's operating margin?
Cartesian (RNAC) had an operating margin of -5127.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Cartesian's net profit margin?
Cartesian (RNAC) had a net profit margin of -4658.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Cartesian's free cash flow?
Cartesian (RNAC) generated -$79.4M in free cash flow during fiscal year 2025. This represents a -142.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Cartesian's operating cash flow?
Cartesian (RNAC) generated -$73.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Cartesian's total assets?
Cartesian (RNAC) had $296.4M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Cartesian's capital expenditures?
Cartesian (RNAC) invested $5.5M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Cartesian spend on research and development?
Cartesian (RNAC) invested $58.0M in research and development during fiscal year 2025.
What is Cartesian's current ratio?
Cartesian (RNAC) had a current ratio of 8.65 as of fiscal year 2025, which is generally considered healthy.
What is Cartesian's debt-to-equity ratio?
Cartesian (RNAC) had a debt-to-equity ratio of -3.35 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Cartesian's return on assets (ROA)?
Cartesian (RNAC) had a return on assets of -44.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Cartesian's cash runway?
Based on fiscal year 2025 data, Cartesian (RNAC) had $125.1M in cash against an annual operating cash burn of $73.9M. This gives an estimated cash runway of approximately 20 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Cartesian's debt-to-equity ratio negative or unusual?
Cartesian (RNAC) has negative shareholder equity of -$126.2M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Cartesian's Altman Z-Score?
Cartesian (RNAC) has an Altman Z-Score of -4.67, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Cartesian's Piotroski F-Score?
Cartesian (RNAC) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Cartesian's earnings high quality?
Cartesian (RNAC) has an earnings quality ratio of 0.57x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Cartesian?
Cartesian (RNAC) scores 36 out of 100 on our Financial Health Score, indicating weak standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.